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Multimodal Nonopioid Pain Protocol Provides Better
or Equivalent Pain Control Compared to Opioid
Analgesia Following Arthroscopic Rotator Cuff
Surgery: A Prospective Randomized Controlled Trial
Touﬁc R. Jildeh, M.D., Muhammad J. Abbas, B.S., Laith Hasan, B.S.,
Vasilios Moutzouros, M.D., and Kelechi R. Okoroha, M.D.

Purpose: To evaluate the efﬁcacy of a multimodal nonopioid analgesic protocol in controlling postoperative pain compared
to opioids following a primary arthroscopic rotator cuff repair. Methods: Seventy consecutive patients undergoing a primary rotator cuff repair were assessed for eligibility. An observer-blinded prospective randomized controlled trial was
designed in accordance with the Consolidated Standards of Reporting Trials 2010 (CONSORT) statement. The two arms of the
study included a multimodal nonopioid pain regimen for the experimental group, and a standard of care narcotics for the
control group. The primary outcome was visual analog scale (VAS) pain scores for the ﬁrst 10 postoperative days. Secondary
outcomes included PROMIS-PI (Patient-Reported Outcomes Measurement Information System-Pain Interference) scale,
patient satisfaction, and adverse drug events. Results: Thirty patients declined to participate or were excluded, and 40
patients were included in the ﬁnal analysis. A total of 23 patients were in the traditional group, and 17 patients were in the
nonopioid group. Control patients on opioid pain management reported a signiﬁcantly higher VAS pain score on postoperative day 1 (opioid: 5.7  2, nonopioid: 3.7  2.2; P ¼ .011) and postoperative day 4 (opioid: 4.4  2.7, nonopioid: 2.4 
2.2; P ¼ .023). No signiﬁcant difference was seen on any other postoperative day. When mixed measured models were used to
control for confounding factors, the nonopioid group demonstrated signiﬁcantly lower VAS and PROMIS-PI scores (P < .01)
at every time point. Patients in the traditional analgesia group reported signiﬁcantly more days with constipation (P ¼ .003)
and days with upset stomach (P ¼ .020) than those in the nonopioid group. Concussion: The present study found that a
multimodal nonopioid pain protocol provided equivalent or better pain control compared to traditional opioid analgesics in
patients undergoing primary arthroscopic rotator cuff repair. Minimal side effects were noted with some improvement in the
multimodal nonopioid pain cohort. All patients reported satisfaction with their pain management. Level of Evidence:
Level I, prospective randomized controlled trial.
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Introduction

P

ostoperative pain management is an essential responsibility of the orthopaedic surgeon. Physicians
have historically managed acute postoperative pain with
the use of opioids; however, opioid misuse and overprescription has been plaguing Americans.1 In 2017,
the National Institutes of Health declared an opioid
epidemic.2 Short-term exposure to narcotics postoperatively creates the risk for long-term misuse, abuse,
and addiction in patients.3 In fact, previous studies have
demonstrated that musculoskeletal conditions are one of
the leading issues associated with the initial prescription
of narcotics, inciting the addictive chain.4 In order to
curtail the risk of narcotic abuse perioperatively, studies
have characterized patient risk factors for prolonged
postoperative opioid use.5,6 Further studies have sought
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Fig 1. CONSORT 2010 ﬂow diagram.

to assess the efﬁcacy of nonopioid analgesics in the
postoperative period.7,8 It is imperative that orthopaedic
surgeons work to minimize the use of narcotics in the
management of postoperative pain.
Studies have demonstrated that 30% of patients over
the age of 60 experience rotator cuff tears, with that
number rising to 62% over the age of 80.9 As the
average age of Americans increases, the incidence of
arthroscopic rotator cuff repair (RCR) in the United
States is expected to experience a concomitant increase.
Previous literature has sought to evaluate pain control
following an arthroscopic RCR.7,10 In a cohort study,
Moutzouros et al. used a nonopioid multimodal pain
regimen consisting of an nonsteroidal antiinﬂammatory drug (NSAID), acetaminophen, diazepam, and gabapentin following common orthopedic
sports procedures and found that a multimodal pain
regimen can provide effective pain control with a
limited side effect proﬁle.7 Magasaki et al. evaluated
pain control following shoulder surgery and found that
patients administered NSAIDs in combination with an
intravenous patient-controlled analgesia (IV PCA) had

signiﬁcantly lower opioid consumption postoperative
compare to patients who received the IV PCA alone.
These studies have demonstrated the value of multimodal analgesic regimens in diminishing the postoperative opioid burden; however, to date, no study has
eliminated the use of narcotics after rotator cuff repair.
The purpose of this randomized controlled trial was to
evaluate the efﬁcacy of a multimodal nonopioid analgesic protocol in controlling postoperative pain
compared to opioids following a primary arthroscopic
rotator cuff repair. The authors hypothesized that our
nonopioid analgesic regimen would provide improved
pain control with no signiﬁcant difference in patientreported adverse drug event between groups.

Methods
This study was a prospective observer-blinded randomized controlled trial with 2-week follow-up and
was developed in accordance with the CONSORT
(Consolidated Standards of Reporting Trials) statement
(Fig 1).11 This investigation received institutional review board approval at our institution (IRB no. 12316)
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Table 1. Multimodal Nonopioid Pain Regimen
Morning
-

Noon

Ketorolac, 10 mg
Gabapentin*, 300 mg
Methocarbamol, 750 mg
Acetaminophen, 1000 mg

-

Postoperative Days 1-5
Afternoon

Ketorolac, 10 mg
Gabapentin, 300 mg
Methocarbamol, 750 mg
Acetaminophen, 1,000 mg

-

Ketorolac, 10 mg
Gabapentin, 300 mg
Methocarbamol, 750 mg
Acetaminophen, 1,000 mg

Evening
- Ketorolac, 10 mg
- Methocarbamol, 750 mg

Postoperative Days 6-14
Morning

Afternoon

- Meloxicam, 7.5 mg
- Methocarbamol, 750 mg
- Acetaminophen, 1,000 mg

Evening

- Meloxicam, 7.5 mg
- Methocarbamol, 750 mg
- Acetaminophen, 1,000 mg

- Methocarbamol 750 mg
- Acetaminophen 1,000 mg

Preoperative by mouth (PO) Regimen: PO celecoxib, 400 mg; acetaminophen, 975 mg; gabapentin, 300 mg; tramadol, 50 mg; dexamethasone,
8 mg iv. Intraoperative Local Inﬁltration Analgesia: 150 mg (30 mL) ropivacaine, 30 mg (1 mL) of ketorolac, and 1 mg (1 mL) of epinephrine
*Gabapentin weaning began on postoperative day 6 in the following manner: 300 mg in the morning and 300 mg in the evening on days 6-7,
400 mg in the morning on days 8-9, and discontinuation on day 10.

and
was
registered
at
ClinicalTrials.gov
(NCT03818919). A hypothesis was formulated prior
to trial initiation. Between August 2019 and December
2020, 70 consecutive patients who presented to two
fellowship-trained sports surgeons and were scheduled
to undergo a primary arthroscopic rotator cuff repair
were screened for inclusion. Inclusion criteria required
patients to be between the ages of 18 and 75 and
scheduled for a primary arthroscopic RCR. Exclusion
criteria included being non-English speaking, history of
ipsilateral surgery in the previous year, undergoing
revision surgery, use of blood thinner medication, history of peptic ulcer disease, history of substance abuse,
and intolerance or allergies to study medication.
Following the surgical consult, patients consented to
participate in the study. Using an adaptive randomization software (MD Anderson Cancer Center, Houston,
TX) with a 1:1 allocation, patients were randomized
into the opioid or nonopioid cohort. A secure computer
database was used to store all deidentiﬁed patient data.
One week prior to the date of surgery, the project
coordinator used a secure e-mail to inform the surgical
staff of the patient’s group designation. Because of the
fact that all outcomes would be self-reported by the
patient, it was not necessary for the treating physician
to be blinded. The research coordinator was not
involved in patient care and performed patient enrollment and data collection.
Intervention
All patients indeterminate of treatment group
received the following medication preoperatively: celecoxib 400 mg, acetaminophen 975 mg, tramadol 50
mg, gabapentin 300 mg, and 8 mg dexamethasone
intravenously. Arthroscopic RCR was performed under
preoperative block. Intraoperatively, all patients
received a local inﬁltration of 30 mg (1 mL) ketorolac, 1

mg (1 mL) epinephrine, and 150 mg (30 mL) of .5%
ropivacaine. Using a 20-mL syringe and 22-gauge
needle, local inﬁltrate was administered in 2-mL increments in the subcutaneous tissue around the portal
sites.
Patients who randomized into the control group were
prescribed 40 pills of 5 mg oxycodone. Patients were
instructed to take 1-2 pills every 4-6 hours as needed
(PRN) and told not to supplement their analgesia with
ibuprofen or acetaminophen.
Patients in the nonopioid group received a multimodal nonopioid analgesic regimen previously
described in the literature.7 The protocol was developed
to target various postoperative pain generators. Gabapentin was used to target neuropathic pain. Methocarbamol was selected because of its excellent control of
muscle spasms and cramps. Acetaminophen and
NSAIDs (ketorolac and meloxicam) were used to target
the pain cascade and the inﬂammatory process. Medication dosage and frequency are listed in Table 1.
Prior to discharge patients were instructed to call the
on-call physician regarding uncontrolled pain or
adverse drug events postoperatively. Patients were
provided an educational pamphlet describing the effects
of narcotics, providing ways to manage pain, and
treatment goals after surgery. All patients were discharged home the same day of surgery.
Outcomes
The data collection was performed by blinded observers. Preoperatively, patients completed the PatientReported Outcomes Measurement and Information
System Pain Interference Short Form (PROMIS PI-SF)
questionnaire. Postoperatively, a mobile messagingbased outcomes collection software (Mosio, Inc, Seattle, WA) was used to collect patient-reported outcomes.
Patients’ responses were submitted as numerical
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response via text message. This process allowed for the
timely collection of data. Surveys were distributed to
patients 3 times daily for 10 postoperative days.
Patient-reported pain scores were collected using a
11-point visual analog scale 3 times a day; in the
morning (9 AM), afternoon (1 PM), and evening (7
PM). Questions regarding adverse drug effects and the
number of opioids consumed in the last 24-hour period
(if applicable) were distributed each evening. Responses
regarding the amount of opioid consumption daily was
converted to morphine milligram equivalents (MME).
During the ﬁrst postoperative clinic visit (Postoperative
days 7-10), patients completed the PROMIS-PI SF
questionnaires.
Information regarding the patients’ demographic data
(age, body mass index [BMI], race), anxiety/depression
status, workers compensation, and previous opioid use
was extracted from the electronic medical record.
Statistical Analysis
A power analysis was performed prior to the initiation
of this investigation. Following a primary arthroscopic
rotator cuff repair, previous literature has indicated that
the minimal clinically signiﬁcant difference (MCID) in
VAS pain scores is 2.4 mm on a 10-mm scale.12 Additionally, a previous case series demonstrated that the
standard of deviation among VAS pain scores in patients following an arthroscopic rotator cuff repair was
2.3 mm on a 10-point scale.7 With a power of 80% (b
level ¼ .80, a level ¼ .05), effect size of 2.4 mm, and
standard deviation of 2.3 mm; the minimum number of
patients was 16 per cohort (n ¼ 32) to evaluate the
primary outcome.
Continuous variables are reported as means and
standard deviations, while frequency counts and percentages are displayed for categorical variables. Comparisons between the two pain control groups
(traditional and nonopioid) are performed using chisquare tests, while Fisher’s exact test is used when expected cell counts are <5. For continuous variables,
two-group comparisons are performed using independent 2-sample t-tests if the variable is normally
distributed and using Wilcoxon rank sum tests if the
variable is non-normally distributed.
Pearson correlation coefﬁcients and their corresponding P values are provided to show the correlation
between select variables for the traditional pain control
group, the nonopioid pain control group, and all
patients.
Repeated-measures analyses of variance were performed using mixed models and included the effects of
time, pain control group, and the interaction between
time and pain control group as applicable. If needed,
signiﬁcant interaction effects were analyzed with post
hoc comparisons using a Tukey-Kramer P value

correction. Predicted means of the outcome variables
resulting from the models were plotted. Statistical signiﬁcance is set at P < .05 for group comparisons and
main effect testing. Signiﬁcance is set at P < .10 for
interaction testing. All analyses are performed using
SAS 9.4 (SAS Institute, Inc., Cary, NC).

Results
Demographics
Seventy consecutive patients with the primary diagnosis of rotator cuff tear were assessed for participation
in the study. Thirty patients either declined to participate or were excluded from the study. A total of 40
patients were included in the ﬁnal analysis, and participants were randomized into 2 groups. Twenty-three
patients were randomized to receive traditional opioid
analgesia, and 17 were randomized to receive nonopioid analgesia. A total of 23 patients in the opioid
group and 17 patients in the nonopioid group were
included in the ﬁnal analysis. All participants had an
average age of 55.1  8.0 years old and an average BMI
of 30.8  5.8. Twenty-ﬁve (56.8%) participants identiﬁed as male, and 19 (43.1%) identiﬁed as female.
Table 2 summarizes all demographic characteristics,
preoperative block type, tear size, number of tendons
Table 2. Demographic Characteristics of Patients on Cohort

Age (years)
Sex
Male
Female
BMI (kg/m2)
Race
White
AA
Other
Preoperative Block
Supraclavicular
Interscalene
Tear Size
Less than 1 cm
1-3 cm
3-5 cm
Greater than 5 cm
Tendons involved
Concomitant Procedures
None
Biceps tenotomy
Biceps tenodesis
DCE
SAD
Anchors (mean  SD)

Traditional
(n ¼ 23)
55.9  7.2

Nonopioid
(n ¼ 17)
53.7  9.1

13 (56.5%)
10 (43.5%)
29.9  5.5

9 (52.9%)
8 (47.1%)
32.2  6.3

.680

14 (60.9%)
7 (30.4%)
2 (8.7%)

7 (41.2%)
8 (47.1%)
2 (11.8%)

.238

5 (21.7%)
18 (78.3%)

3 (17.6%)
14 (82.4%)

.758

4 (14.8%)
16 (69.6%)
2 (8.7%)
1 (4.3%)
1.4  .8

1 (5.8%)
11 (64.7%)
5 (29.4%)
0 (0%)
1.7  .4

.777

2 (8.7%)
2 (8.7%)
3 (48.3%)
2 (8.7%)
14 (60.9%)
2.6  1.1

0 (0%)
2 (11.8%)
4 (23.5%)
1 (5.9%)
10 (58.8%)
2.7  .8

.479

P Value
.382

.218

.194

.770

Bold values denote statistical signiﬁcance (P < .05).
AA, African American; BMI, body mass index; DCE, distal clavicle
excision; SAD, subacromial decompression.
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Fig 2. Average daily visual analog scale (VAS) pain score of patients of traditional and nonopioid pain regimen. *Values denote
statistical signiﬁcance (P < .05).

involved and codominant procedures between the two
cohorts. There were no workers compensation claims.
Traditional Versus Nonopioid Analgesia
Patients in the traditional pain control group reported a
signiﬁcantly higher VAS pain score on postoperative day 1
(opioid: 5.7  2, nonopioid: 3.7  2.2; P ¼ .011, Fig 2) and
postoperative day 4 (opioid: 4.4  2.7, nonopioid: 2.4  2.2;
P ¼ .023). No signiﬁcant difference was seen on any other
postoperative day. There were no signiﬁcant differences in
PROMIS PI-SF scores between both groups preoperatively
(opioid: 64.4  4.2, nonopioid: 62.9  4.3; P ¼ .0291) and
postoperatively (opioid: 60.0  9.3, nonopioid: 59.3  8.5;
P ¼ .805). Following a repeated-measure, mixed-model
analysis to assess covariates, the mean VAS score was
signiﬁcantly greater in the traditional group than in the
nonopioid group across all postoperative days (P < .01)
(Fig 3). Mixed-measures models also demonstrated that
there was no signiﬁcant difference in postoperative
PROMIS-PI scores between cohorts (P ¼ .49) (Fig 4). In the
traditional pain control group, the highest opioid consumption, as reported on postoperative day 1-3 (POD 1: 3.7
 1.3 pills, 28.3  9.1 MME; POD 2: 3.4  2.4 pills, 26.3 
17.7 MME; and POD 3: 2.8  1.8 pills, 21.2  13.3 MME)
and lowest on postoperative days 8-10 (POD8: 1.1  1.4
pills, 8.3  10.9 MME; POD 9: .8  1.2, 5.4  8.8 MME; and
POD 10: 1.2  1.7, 6.7  9.9 MME) (Fig 5).
When evaluating all patients as a whole, patient
demographics (age, gender, BMI, and ethnicity) and

concomitant procedures did not have a statistically
signiﬁcant relationship with postoperative VAS scores
or MME (P > .05).
Adverse Events
There was no signiﬁcant difference in the number of days
patients reported any adverse events (opioid: 4.1  3.5
days, nonopioid: 2.2  3.4 days; P ¼ .08). The most
commonly reported side effects for patients in both groups
were drowsiness (opioid: 2.7  3.3 days, nonopioid: 1.9 
3.3 days) and constipation (opioid: 2.2  2.9 days, nonopioid: .2  .6 days). Patients in the traditional analgesia
group reported signiﬁcantly greater average number of
days with constipation (opioid: 2.2  2.9, nonopioid: .2 
.6; P ¼ .003) and days with upset stomach (opioid: 1.3 
2.5, nonopioid: .0  .0; P ¼ .020) than those in the nonopioid group. Additionally, there was no signiﬁcant difference for nausea (P ¼ .06), diarrhea (P ¼ .46), drowsiness
(P ¼ .33), or dizziness (P ¼ .68) between cohorts. Table 3
summarizes side effects for both cohorts. All (100%) patients in the nonopioid protocol reported they were satisﬁed with their pain management. There were no reported
complications with the nonopioid protocol, and no patients
required emergency opioid analgesia.

Discussion
The current study found that the multimodal nonopioid analgesic protocol provided at least equivalent
postoperative pain management with a similar or lesser
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Fig 3. Mean hourly pain data controlling for age, graft, body mass index, sex, smoking, and depression
comparing daily pain levels between
the two groups. The mean visual
analog scale (VAS) score is signiﬁcantly greater in the traditional
group than in the nonopioid group
(P < .01).

side effect proﬁle compared to traditional opioid analgesia. In conjunction with national efforts to reduce
opioid addiction and consumption, the results suggest a
multimodal nonopioid pain protocol may be an effective alternative for postoperative pain management
following arthroscopic RCR.

Reports of postoperative pain protocols successfully
eliminating opioids have been promising but limited in
the literature. Previous studies have suggested a potential beneﬁt to postoperative nonopioid pain management, including alternatives such as NSAIDs,
gabapentin, cryotherapy, local anesthesia injections,

Fig 4. PROMIS PI-SF (Patient-Reported Outcomes Measurement Information System-Pain InterferenceShort Form) controlling for age, sex,
body mass index, smoking, and
depression. No signiﬁcant difference
in PROMIS PI was found between
the two groups (P ¼ .49).
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Fig 5. Predicted mean MME for
opioid group when controlling for
age, sex, body mass index, smoking,
and depression. Morphine equivalent usage was found to decrease as
time from surgery increased (specifically, from sequential day to day).
Time was found to be a signiﬁcant
factor (P < .0001). MME, morphine
milligram equivalents.

and nerve blocks.13 A randomized control trial by Syed
et al. demonstrated opioid-related preoperative education alone signiﬁcantly reduced opioid consumption at
6 weeks (P ¼ .02) and 3 months (P ¼ .01) after
arthroscopic RCR.14,15 In a randomized control trial
investigating the addition of liposomal bupivacaine injection to multimodal anesthetic protocols in primary
RCR, Sethi et al. found a signiﬁcant reduction in postoperative pain in days 1 (P < .001) and 2 (P ¼ .03) and
the number of opioids used in the ﬁrst 5 days after
arthroscopic RCR (P ¼ .003) compared to the control
group.16 In a prospective study of 36 patients investigating the use of ketorolac, zolpidem, and acetaminophen as an alternative to opioids following RCR,
Theosmy et al. found that 67% of patients successfully
completed opioid-free arthroscopic RCR.17 They also
found that patients who did not take opioids postoperatively demonstrated higher satisfaction with their
Table 3. Average Number of Days Side Effects Were Reported
in the Traditional and Nonopioid Pain Protocol

Total
Total
Total
Total
Total
Total

constipated days
nausea days
diarrhea days
upset stomach days
drowsiness days
dizziness days

Traditional
(n ¼ 23)
2.2  2.9
1.0  1.6
.1  .2
1.3  2.5
2.7  3.3
.4  1.0

Nonopioid
(n ¼ 17)
.2  .6
.1 .3
.0  .0
.0  .0
1.9  3.3
.2  .4

P Value
.003
.066
.457
.020
.327
.681

Values are expressed as mean days  SD. Bold values denote statistical signiﬁcance (P < .05).

pain management. Finally, in a case series by Moutzouros et al. of 141 patients (27 RCR) using an identical
nonopioid pain protocol to the current study, they
found that 45% of all patients did not require any
breakthrough opioids, and the average VAS pain score
at 1 week postoperatively was 3.9  2.8 following
RCR.7 In accordance with previous literature, the present study demonstrates that equivalent pain control
postoperative as reported by VAS pain scores. Additionally, patients in the nonopioid group reported a
statistically signiﬁcant decrease in VAS scores when
controlling for confounding variables. All patients in the
present study reported 100% satisfaction with their
respective pain control regimens, highlighting that
postoperative pain control and patient satisfaction can
be achieved while minimizing the risk of opioid addition postoperatively.
When deciding on a postoperative pain regiment, it is
essential to consider how to best maximize therapeutic
beneﬁt while minimizing adverse events and side effects for patients. Opioids have a broad side effect proﬁle,
most
commonly,
including
drowsiness,
gastrointestinal issues, such as constipation and nausea,
and vomiting.18 In a survey of 500 patients assessing
their perception of treatment with opioids, respondents
reported nausea (78%) and constipation (64%) as the
most common causes for discontinuing opioids.19 In a
prior case series using a nonopioid analgesia protocol,
Moutzouros et al. found that 53.6% of patients reported no adverse effects of their pain regimen, with
the most commonly reported side effects in both groups
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being constipation (opioid: 1.9  2.9; nonopioid: .9 
2.0) and drowsiness (opioid: 2.5  3.6; nonopioid: 1.0
 1.6).7 The current study demonstrated that the
multimodal analgesia cohort had signiﬁcantly fewer
total constipated days and upset stomach days than the
traditional opioid analgesia cohort, suggesting
improved gastrointestinal side effect experiences for
patients with no compromise on pain control. The
current study also demonstrated a nonsigniﬁcant
decrease in total nausea days (1.0 in the opioid cohort
vs .1 in the nonopioid cohort). Opioid medications are a
well-known source of sedation and drowsiness in patients.20 Dizziness or drowsiness may also be caused by
methocarbamol and gabapentin; however a randomized controlled trial investigating gabapentin use
following shoulder arthroscopy demonstrated that the
use of gabapentin had no signiﬁcant differences in
somnolence-dizziness and nausea-vomiting and
increased patient satisfaction.21-23 While the multimodal pain control regimen may present concerns
regarding the use of NSAIDs and tendon to bone
healing, a meta-analysis by Duchman et al. demonstrated that there is not sufﬁcient evidence in the
literature supporting the avoidance of NSAIDs
following acute injury or surgical repair of the tendonbone interface; however, this is an area that warrants
further investigation.24
Previous literature has assessed pain control and
MME levels and its correlation with demographic
characteristics and concomitant procedures. In a retrospective analysis investigating chronic opioid use
following surgery, Sun et al. found that preoperative
history of drug or alcohol abuse, depression, benzodiazepine use, or antidepressant use were associated with
chronic opioid consumption postoperatively.25 Additionally, Sun et al. also found that men were associated
with chronic opioid use following surgery. In a cohort
study examining factors that predicted the severity of
postoperative pain after RCR surgery Rizvi et al. found
that tendon tear size was inversely related with pain
severity (R2 ¼ .85). Additionally, they demonstrated
that other factors associated with postoperative pain
frequency included work-related injury status (P <
.001), younger age (P ¼ .001), and female sex (P ¼ .04).
The current study revealed no correlation between
gender, concomitant procedures, and VAS scores, and
no association with tendon tear size. Since pain
perception and tolerance may be inﬂuenced by a wide
range of factors, this area warrants further investigation
to provide the most effective pain management for
patients.
Limitations
This study is not without limitations. Because of the
study design, double blinding was not possible, since
patients were informed of their postoperative

treatment. Consequently, this made bias in patientreported pain scores possible. Furthermore, we were
unable to measure patient compliance with medication,
which may have further inﬂuenced pain scores as patients could opt to not take their medication. Additionally, this study was only powered to assess the
primary outcome of VAS scores postoperatively. The
sample size was not large enough to perform a
comprehensive subgroup analysis for all demographic
characteristics and concomitant procedures. A high
number of patients declined to participate because of
the predetermined preferences for postoperative analgesia. These patients did not want to risk randomization
and not receiving their desired pain regimen. Although
this may have impacted the study group, it is important
to note that it was not possible to blind patients to their
medication, particularly when evaluating side effect
proﬁle of each regimen. Finally, it was not possible to
evaluate the total pain reduction possible with the
nonopioid pain regimen, as it would be unethical to
withhold pain medication from patients following
surgery.
Conclusion
The present study found that a multimodal nonopioid
pain protocol provided equivalent or better pain control
compared to traditional opioid analgesics in patients undergoing primary arthroscopic rotator cuff repair. Minimal side effects were noted with some improvement in
the multimodal nonopioid pain cohort, and all patients
reported satisfaction with their pain management.
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